Our Services

Garrett Vygantas, MD, MBA is Founder & Managing Partner of Riverine Ventures, a life science and healthcare dedicated venture capital firm. Trained as a physician and an experienced entrepreneur, Garrett provides strategic direction and valuable clinical and commercial networks as a Board Member or Advisor to Adventris Pharma, AEye Health, ArtiSight, CellFE, Ceria Therapeutics, Corsair Pharma, Eliksa Therapeutics, HealthBridge, Inflammatix, KeifeRx, Mediphage and Pieces Technologies.

His previous investments include Aptinyx (NASDAQ: APTX), Circularis (acq. by Ginkgo Bio, NYSE: DNA), Doctor on Demand (acq. by Grand Rounds), Endotronix, Exo Imaging, Health Scholars, Gauss Surgical (acq. by Stryker, NYSE: SYK), Level Ex (acq. by Brainlab), MediBeacon, Paradigm Cancer Diagnostics (acq. by Exact Sciences, NASDAQ: EXAS), Rayze Bio (acq. by Bristol Myers Squibb, NYSE: BMY), SilverCloud (acq. by AmWell, NYSE: AMWL), Spect, Stem (NYSE: STEM) and Visibly.

With over 20 years, Garrett’s expertise spans across biopharma, life sciences, healthcare, medtech and digital health investing and operations. Before founding Riverine Ventures, he has invested on behalf of The 4100 Group, OSF Healthcare, Jump Capital and Burrill & Co. As an operator, he served as Founding CEO of TherOptix, NewBridge Pharmaceuticals and Mitre Medical and Chief Business Officer of Corsair Pharma. At NewBridge, he and his team raised over $60M in financing and created $470M in nominal value.

Earlier in his career Garrett helped launch Lucentis at Genentech and worked on the healthcare investment banking team at Cowen & Company. He earned his MD /MBA degree from Georgetown University and completed his residency at the University of Pennsylvania. He is a Kauffman Fellow and Mentor at the Center for Venture Education and has served on numerous not-for-profit Boards.

Scott Robert Lancaster, MD, MBA is a venture capitalist, board certified diagnostic radiologist and real estate entrepreneur with proven success in clinical medicine, practice management, corporate leadership and contract negotiations. His ability to apply business theory and systems thinking to the healthcare investment arena directly impacts the quadruple aim of healthcare and represents a balance of clinical, economic and humanistic factors - all in the interest of creating both immediate and future shared value.

As co-lead and clinical director of Spectrum Health Ventures ($100M venture arm of Spectrum Health System), Scott led investments in Arivale, Gauss Surgical (acquired by Stryker), Ciitizen (acquired by Invitae) and Vynca. As Managing Director and Chief Investment Officer for The 4100 Group, Inc. he has led investments across all asset classes in The 4100 Group’s permanent capital vehicle.Over a 18+ year career as a practicing radiologist at Advanced Radiology Services, he served as the longtime clinical director of musculoskeletal imaging at Spectrum Health and was transformative in implementing musculoskeletal ultrasound as a diagnostic tool in clinical practice. At Advanced Radiology Services, he served as a multi-year board director, practice vice president and president of the Advanced Radiology Services Foundation.

Dr. Lancaster and his wife Maggie, the CEO of the Grand Rapids Children’s Museum, have been heavily involved in the non-profit sector throughout West Michigan at Spectrum Health, the Grand Rapids Children’s Museum, the Grand Rapids Public Museum, Make-A-Wish Foundation, CASA and Family Futures.